However, even if NANEPs only extend the initial survival period from diagnosis after current treatments (between 11 and 31 months depending on IDH and MGMT status: https://www.abta.org/tumor_types/glioblastoma-gbm/), this would be an important improvement. This evidence concerns the gene MGMT and glioblastoma.